National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

NCPE Assessment Process Complete
Rapid review commissioned 04/03/2019
Rapid review completed 22/05/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that risankizumab not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013